Haohan Karen Wei
Chen Zhao
Chengcheng Jin
1 Thoracic and Gastrointestinal Malignancies Branch, National Cancer Institute, National Institutes of Health, 4 Memorial Drive, Bethesda, MD 20892, USA;
2 Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., Philadelphia, PA 19104, USA
Funds: Figures are created with BioRender. C.J. is supported in part by a R00 Award from NIH/NCI (CA226400), an Emerson Collective Cancer Research Fund, and a Lung Cancer Research Foundation (LCRF) Pilot Grant. C.Z. is supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, SITC-AstraZeneca Immunotherapy in Lung Cancer (Early Stage NSCLC) Clinical Fellowship Award.
Received Date: 2020-08-23
Rev Recd Date:2020-11-01
Abstract
Abstract
Although intestinal microbiome have been established as an important biomarker and regulator of cancer development and therapeutic response, less is known about the role of microbiome at other body sites in cancer. Emerging evidence has revealed that the local microbiota make up an important part of the tumor microenvironment across many types of cancer, especially in cancers arising from mucosal sites, including the lung, skin and gastrointestinal tract. The populations of bacteria that reside specifically within tumors have been found to be tumor-type specific, and mechanistic studies have demonstrated that tumor-associated microbiota may directly regulate cancer initiation, progression and responses to chemo- or immuno-therapies. This review aims to provide a comprehensive review of the important literature on the microbiota in the cancerous tissue, and their function and mechanism of action in cancer development and treatment.Keywords: microbiome,
tumor,
lung cancer,
immune system,
tumor-associated microbiota,
cancer immunotherapy
PDF全文下载地址:
http://www.protein-cell.org/article/exportPdf?id=e3874cd4-39d5-4fdb-b239-709efff0ff03&language=en
